CATEGORIES: Pneumonia; Infection, skin and skin structure; Infection, urinary tract; Gonorrhea; Infection, ear, middle; Infection, genital tract; Infection, lower respiratory tract; Infection, upper respiratory tract; Infection, sinus; Pharyngitis; Ulcer, H. pylori associated; Tonsillitis; Pregnancy Category B; WHO Formulary; FDA Approved August 1979
Drug Classes: Antibiotics, penicillins
BRAND NAMES: Amoxicot; Amoxil; Amoxil Pediatric Drops; Biomox; Dispermox; Moxilin; Trimox; Wymox
FOREIGN BRAND AVAILABILITY:
Abdimox (Indonesia);
Acimox (Mexico);
Acticillin (Thailand);
Actimoxi (Spain);
Adbiotin (Colombia);
Agerpen (Spain);
A-Gram (France);
Alfamox (Italy);
Almodan (England);
Amagesen Solutab (Germany);
Ameclina (Mexico);
Amoclen (Czech Republic);
Amodex (France);
Amo-flamsian (Spain);
Amohexal (Australia);
Amolin (Japan, Taiwan);
Amophar GE (France);
Amosine (Indonesia);
Amoval (Peru);
Amox (Italy);
Amoxa (Hong Kong, Singapore);
Amoxal (Colombia);
Amoxapen (Hong Kong, Korea, Singapore);
Amoxaren (Spain);
Amoxcillin (Thailand);
Amoxi (Israel);
Amoxi-basan (Germany);
Amoxicilina (Colombia, Ecuador);
Amoxiclin (Peru);
Amoxidal (Argentina);
Amoxihexal (Germany);
Amoxillin (Israel, Italy, Norway);
Amoxipen (Italy, Peru);
Amoxisol (Mexico);
Amoxivan (India);
Amoxivet (Mexico);
Amoxy (Thailand);
Amoxy-diolan (Germany);
Amoxypen (Germany, Peru);
Apo-Amoxi (Malaysia);
Ardine (Mexico, Spain);
Aroxin (Singapore);
Azillin (Switzerland);
Bactamox (Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras, Nicaragua, Panama);
Bimox (Colombia);
Bintamox (Indonesia);
Bioxidona (Spain);
Bioxyllin (Indonesia);
Bristamox (Ecuador, France, Peru, Sweden);
Broadmetz (Philippines);
Cilamox (Philippines);
Clamox (Finland);
Clamoxyl (Austria, Belgium, France, Germany, Japan, Netherlands, Peru, Portugal, Spain, Switzerland);
Clonamox (China);
Coamoxin (Spain);
Doxamil (Mexico);
Draximox (Denmark);
Edamox (Hong Kong);
Efpinex (Japan);
Eupen (Dominican Republic, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Spain);
Flemoxin (China);
Flemoxine Ge (France);
Foxolin (Korea);
Fullcilina (Argentina);
Gexcil (Philippines);
Gimalxina (Mexico);
Gomcillin (Korea);
Grinsul (Argentina);
Grunamox (Ecuador);
Hamoxillin (Hong Kong);
Hiconcil (Belgium, Bulgaria, France, Indonesia, Israel, Netherlands);
Hidramox (Mexico);
Hosboral (Spain);
Ibiamox (Israel, Taiwan, Thailand);
Ikamoxil (Indonesia);
Imacillin (Denmark, Norway, Sweden);
Imaxilin (Colombia);
Intermox (Philippines);
Isimoxin (Italy);
Julphamox (Peru);
Kamoxin (Thailand);
Ladoxillin (Philippines);
Lamoxy (India);
Larocilin (Argentina);
Magnimox (Peru);
Maxamox (New Zealand);
Maxcil (South Africa);
Medimox (Indonesia);
Meixil (Thailand);
Mopen (Italy);
Morgenxil (Spain);
Mox (India);
Moxacin (New Zealand);
Moxaline (Belgium);
Moxilen (Hong Kong, Taiwan);
Moximar (Philippines);
Moxtid (Indonesia);
Moxylin (Ecuador);
Moxypen (Israel, South Africa);
Moxyvit (Israel);
Neogram (Colombia);
Novabritine (Belgium);
Novamox (Philippines);
Novamoxin (Canada);
Novenzymin (Argentina);
Optium (Argentina);
Ospamox (Austria, Bulgaria, Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras, Hong Kong, Indonesia, Malaysia, New Zealand, Nicaragua, Panama, Peru, Portugal);
Pamocil (Italy);
Pamoxicillin (Taiwan);
Pamoxin (Korea);
Panvilon (Philippines);
Pasetocin (Japan);
Penamox (Argentina, China, Mexico, Peru);
Penbiosyn (Philippines);
Rancil (Thailand);
Ranmoxy (South Africa);
Ranoxyl (Malaysia);
Robamox (Indonesia);
Rocillin (South Africa);
Romoxil (Philippines);
Ronemox (India);
Saltermox (South Africa);
Sawacillin (Japan);
Sawamezin (Japan);
Servamox (Taiwan);
Shamoxil (Israel);
Sia-mox (Thailand);
Sil-A-mox (Thailand);
Simoxil (Italy);
Solpenox (Indonesia);
Superpeni (Spain);
Teramoxyl (Philippines);
Tolodina
COST OF THERAPY:
|
Amoxicillin is a semisynthetic antibiotic, an analog of ampicillin, with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms. Chemically it is (2S,5R,6R)-6-[(R)-(-)-2-amino-2-(p-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate.
The amoxicillin molecular formula is C16H19N3O5S·3H2O, and the molecular weight is 419.45.
Amoxil capsules, tablets, and powder for oral suspension are intended for oral administration.
Capsules
Each Amoxil capsule, with royal blue opaque cap and pink opaque body, contains 250 or 500 mg amoxicillin as the trihydrate. Inactive Ingredients: D&C red no. 28, FD&C blue no. 1, FD&C red no. 40, gelatin, magnesium stearate, and titanium dioxide.
Tablets
Each tablet contains 500 or 875 mg amoxicillin as the trihydrate. Inactive Ingredients: Colloidal silicon dioxide, crospovidone, FD&C red no. 30 aluminum lake, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, and titanium dioxide.
Chewable Tablets
Each cherry-banana-peppermint-flavored tablet contains 200 or 400 mg amoxicillin as the trihydrate.
Each 200 mg chewable table contains 0.0005 mEq (0.0107 mg) of sodium; the 400 mg chewable tablet contains 0.0009 mEq (0.0215 mg) of sodium. 200 and 400 mg Inactive Ingredients: Aspartame, crospovidone, FD&C red no. 40 aluminum lake, flavorings, magnesium stearate, and mannitol.
See PRECAUTIONS.
Powder for Oral Suspension
Each 5 milllileter of reconstituted suspension contains 125, 200, 250, or 400 mg amoxicillin as the trihydrate. Each 5 ml of the 125 mg reconstituted suspension contains 0.11 mEq (2.51 mg) of sodium; each 5 ml of the 250 mg reconstituted suspension contains 0.15 mEq (3.36 mg) of sodium. Each 5 ml of the 200 mg reconstituted suspension contains 0.15 mEq (3.39 mg) of sodium; each 5 ml of the 400 mg reconstituted suspension contains 0.19 mEq (4.33 mg) of sodium.
Pediatric Drops for Oral Suspension
Each ml of reconstituted suspension contains 50 mg amoxicillin as the trihydrate and 0.03 mEq (0.69 mg) of sodium.
Amoxicillin trihydrate for oral suspension 125 mg/5 ml (reconstituted) is a strawberry-flavored pink suspension; the 200, 250 (or 50 mg/ml), and 400 mg/5 ml are bubble-gum-flavored pink suspensions. Inactive Ingredients: FD&C red no. 3, flavorings, silica gel, sodium benzoate, sodium citrate, sucrose, and xanthan gum.
Amoxicillin is stable in the presence of gastric acid and is rapidly absorbed after oral administration. The effect of food on the absorption of amoxicillin from amoxicillin tablets and suspension has been partially investigated. The 400 and 875 mg formulations have been studied only when administered at the start of a light meal. However, food effect studies have not been performed with the 200 and 500 mg formulations. Amoxicillin diffuses readily into most body tissues and fluids, with the exception of brain and spinal fluid, except when meninges are inflamed. The half-life of amoxicillin is 61.3 minutes. Most of the amoxicillin is excreted unchanged in the urine; its excretion can be delayed by concurrent administration of probenecid. In blood serum, amoxicillin is approximately 20% protein-bound.
Orally administered doses of 250 and 500 mg amoxicillin capsules result in average peak blood levels 1-2 hours after administration in the range of 3.5-5.0 μg/ml and 5.5-7.5 μg/ml, respectively.
Mean amoxicillin pharmacokinetic parameters from an open, two-part, single-dose crossover bioequivalence study in 27 adults comparing 875 mg of amoxicillin with 875 mg of amoxicillin/clavulanate potassium showed that the 875 mg tablet of amoxicillin produces an AUC(0-∞) of 35.4 ± 8.1 μg·h/ml and a Cmax of 13.8 ± 4.1 μg/ml. Dosing was at the start of a light meal following an overnight fast.
Orally administered doses of amoxicillin suspension, 125 and 250 mg/5 ml, result in average peak blood levels 1-2 hours after administration in the range of 1.5-3.0 μg/ml and 3.5-5.0 μg/ml, respectively.
Oral administration of single doses of 400 mg amoxicillin chewable tablets and 400 mg/5 ml suspension to 24 adult volunteers yielded comparable pharmacokinetic data (see TABLE 1).
Detectable serum levels are observed up to 8 hours after an orally administered dose of amoxicillin. Following a 1 g dose and utilizing a special skin window technique to determine levels of the antibiotic, it was noted that therapeutic levels were found in the interstitial fluid. Approximately 60% of an orally administered dose of amoxicillin is excreted in the urine within 6-8 hours.
Microbiology
Amoxicillin is similar to ampicillin in its bactericidal action against susceptible organisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell wall mucopeptide. Amoxicillin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in INDICATIONS AND USAGE.
Aerobic Gram-Positive Microorganisms:
*Staphylococci which are susceptible to amoxicillin but resistant to methicillin/oxacillin should be considered as resistant to amoxicillin.
Aerobic Gram-Negative Microorganisms:
Helicobacter:
Susceptibility Testing
Dilution Techniques
Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method 1 (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of ampicillin powder. Ampicillin is sometimes used to predict susceptibility of Streptococcus pneumoniae to amoxicillin; however, some intermediate strains have been shown to be susceptible to amoxicillin. Therefore, Streptococcus pneumoniae susceptibility should be tested using amoxicillin powder. The MIC values should be interpreted according to the criteria in TABLE 2 and TABLE 3.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| * Staphylococci which are susceptible to amoxicillin but resistant to methicillin/oxacillin should be considered as resistant to amoxicillin. | |||||||||||||||||||||||||||||||||||||||||||||||||||
| † These interpretive standards are applicable only to broth microdilution susceptibility tests using cation-adjusted Mueller-Hinton broth with 2-5% lysed horse blood. | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Note: These criteria are based on the recommended doses for respiratory tract infections. | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| * These interpretive standards are applicable only to broth microdilution test with Haemophilus influenzae using Haemophilus Test Medium (HTM). 1 | ||||||||||||||||||||||||||||||
A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of “Intermediate” indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.
Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard ampicillin powder should provide the MIC values found in TABLE 4 and TABLE 5.
|
||||||||||||
| * This quality control range is applicable to only H. influenzae ATCC 49247 tested by a broth microdilution procedure using HTM. 1 | ||||||||||||
|
||||||
| * This quality control range is applicable to only S. pneumoniae ATCC 49619 tested by the broth microdilution procedure using cation-adjusted Mueller-Hinton broth with 2-5% lysed horse blood. | ||||||
Diffusion Techniques
Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure 2 requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 10 μg ampicillin to test the susceptibility of microorganisms, except S. pneumoniae, to amoxicillin. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for ampicillin.
Reports from the laboratory providing results of the standard single-disk susceptibility test with a 10 μg ampicillin disk should be interpreted according to the criteria found in TABLE 6 and TABLE 7.
|
||||||||||||||||||||||||||||||||||||
| * Staphylococci which are susceptible to amoxicillin but resistant to methicillin/oxacillin should be considered as resistant to amoxicillin. | ||||||||||||||||||||||||||||||||||||
Note: For streptococci (other than β-hemolytic streptococci and S. pneumoniae), an ampicillin MIC should be determined.
S. pneumoniae
S. pneumoniae should be tested using a 1 μg oxacillin disk. Isolates with oxacillin zone sizes of ≥20 mm are susceptible to amoxicillin. An amoxicillin MIC should be determined on isolates of S. pneumoniae with oxacillin zone sizes of ≤19 mm.
|
||||||||||||||||||||||||||||||
| * These interpretive standards are applicable only to disk diffusion susceptibility tests with H. influenzae using Haemophilus Test Medium (HTM). 2 | ||||||||||||||||||||||||||||||
Interpretation should be as stated above for results using dilution techniques.
As with standard dilution techniques, disk diffusion susceptibility test procedures require the use of laboratory control microorganisms. The 10 μg ampicillin disk should provide the following zone diameters in these laboratory test quality control strains (see TABLE 8 and TABLE 9).
|
||||||||||
| * This quality control range is applicable to only H. influenzae ATCC 49247 tested by a disk diffusion procedure using HTM. 2 | ||||||||||
|
||||||
| * This quality control range is applicable to only S. pneumoniae ATCC 49619 tested by a disk diffusion procedure using Mueller-Hinton agar supplemented with 5% sheep blood and incubated in 5% CO2. | ||||||
Susceptibility Testing for Helicobacter pylori
In vitro susceptibility testing methods and diagnostic products currently available for determining minimum inhibitory concentrations (MICs) and zone sizes have not been standardized, validated, or approved for testing H. pylori microorganisms.
Culture and susceptibility testing should be obtained in patients who fail triple therapy. If clarithromycin resistance is found, a non-clarithromycin-containing regimen should be used.
H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence
Randomized, double-blind clinical studies performed in the US in patients with H. pylori and duodenal ulcer disease (defined as an active ulcer or history of an ulcer within 1 year) evaluated the efficacy of lansoprazole in combination with amoxicillin capsules and clarithromycin tablets as triple 14 day therapy, or in combination with amoxicillin capsules as dual 14 day therapy, for the eradication of H. pylori. Based on the results of these studies, the safety and efficacy of two different eradication regimens were established.
All treatments were for 14 days. H. pylori eradication was defined as two negative tests (culture and histology) at 4-6 weeks following the end of treatment.
Triple therapy was shown to be more effective than all possible dual therapy combinations. Dual therapy was shown to be more effective than both monotherapies. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
|
||||||||||||||||||||||||||||||
| * This analysis was based on evaluable patients with confirmed duodenal ulcer (active or within 1 year) and H. pylori infection at baseline defined as at least 2 of 3 positive endoscopic tests from CLOtest, (Delta West Ltd., Bentley, Australia), histology and/or culture. Patients were included in the analysis if they completed the study. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as failures of therapy. | ||||||||||||||||||||||||||||||
| † Patients were included in the analysis if they had documented H. pylori infection at baseline as defined above and had a confirmed duodenal ulcer (active or within 1 year). All dropouts were included as failures of therapy. | ||||||||||||||||||||||||||||||
| ‡ (p <0.05) versus lansoprazole/amoxicillin and lansoprazole/clarithromycin dual therapy. | ||||||||||||||||||||||||||||||
| § (p <0.05) versus clarithromycin/amoxicillin dual therapy. | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| * This analysis was based on evaluable patients with confirmed duodenal ulcer (active or within 1 year) and H. pylori infection at baseline defined as at least 2 of 3 positive endoscopic tests from CLOtest, histology and/or culture. Patients were included in the analysis if they completed the study. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as failures of therapy. | ||||||||||||||||||||||||||||||
| † Patients were included in the analysis if they had documented H. pylori infection at baseline as defined above and had a confirmed duodenal ulcer (active or within 1 year). All dropouts were included as failures of therapy. | ||||||||||||||||||||||||||||||
| ‡ (p <0.05) vs lansoprazole alone. | ||||||||||||||||||||||||||||||
| § (p <0.05) vs lansoprazole alone or amoxicillin alone. | ||||||||||||||||||||||||||||||
Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) strains of the designated microorganisms in the conditions listed below:
Therapy may be instituted prior to obtaining results from bacteriological and susceptibility studies to determine the causative organisms and their susceptibility to amoxicillin.
Indicated surgical procedures should be performed.
H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence
Triple Therapy
Amoxicillin/Clarithromycin/Lansoprazole
Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1 year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence (see CLINICAL STUDIES and DOSAGE AND ADMINISTRATION).
Dual Therapy
Amoxicillin/Lansoprazole
Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1 year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the CLINICAL PHARMACOLOGY, Microbiology section of the clarithromycin product information.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.)
Non-FDA Approved Indications
In addition, amoxicillin may be used for the treatment of actinomycosis and Lyme disease, although these uses have not been approved by the FDA.
A history of allergic reaction to any of the penicillins is a contraindication.
SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (ANAPHYLACTIC) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY. ALTHOUGH ANAPHYLAXIS IS MORE FREQUENT FOLLOWING PARENTERAL THERAPY, IT HAS OCCURRED IN PATIENTS ON ORAL PENICILLINS. THESE REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS. BEFORE INITIATING THERAPY WITH AMOXICILLIN, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS. IF AN ALLERGIC REACTION OCCURS, AMOXICILLIN SHOULD BE DISCONTINUED AND APPROPRIATE THERAPY INSTITUTED. SERIOUS ANAPHYLACTIC REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, IV STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.
Pseudomembranous colitis has been reported with nearly all antibacterial agents, including amoxicillin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.
Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of “antibiotic-associated colitis”.
After the diagnosis of pseudomembranous colitis has been established, appropriate therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against Clostridium difficile colitis.
General
The possibility of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy. If superinfections occur, amoxicillin should be discontinued and appropriate therapy instituted.
Phenylketonurics
Each 200 mg amoxicillin chewable tablet contains 1.82 mg phenylalanine; each 400 mg chewable tablet contains 3.64 phenylalanine. The amoxicillin suspensions do not contain phenylalanine and can be used by phenylketonurics.
Laboratory Tests
As with any potent drug, periodic assessment of renal, hepatic, and hematopoietic function should be made during prolonged therapy.
All patients with gonorrhea should have a serologic test for syphilis at the time of diagnosis. Patients treated with amoxicillin should have a follow-up serologic test for syphilis after 3 months.
Drug/Laboratory Test Interactions
High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using Clinitest, Benedict's Solution or Fehling's Solution. Since this effect may also occur with amoxicillin, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix or Tes-Tape) be used.
Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted. This effect may also occur with amoxicillin.
Carcinogenesis, Mutagenesis, and Impairment of Fertility
Long-term studies in animals have not been performed to evaluate carcinogenic potential. Studies to detect mutagenic potential of amoxicillin alone have not been conducted; however, the following information is available from tests on a 4:1 mixture of amoxicillin and potassium clavulanate. Amoxicillin; potassium clavulanate was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. Amoxicillin; potassium clavulanate was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival. Amoxicillin; potassium clavulanate was negative in the mouse micronucleus test, and in the dominant lethal assay in mice. Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays. In a multi-generation reproduction study in rats, no impairment of fertility or other adverse reproductive effects were seen at doses up to 500 mg/kg (approximately 3 times the human dose in mg/m2).
Pregnancy, Teratogenic Effects, Pregnancy Category B
Reproduction studies have been performed in mice and rats at doses up to 10 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to amoxicillin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Labor and Delivery
Oral ampicillin-class antibiotics are poorly absorbed during labor. Studies in guinea pigs showed that IV administration of ampicillin slightly decreased the uterine tone and frequency of contractions but moderately increased the height and duration of contractions. However, it is not known whether use of amoxicillin in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.
Nursing Mothers
Penicillins have been shown to be excreted in human milk. Amoxicillin use by nursing mothers may lead to sensitization of infants. Caution should be exercised when amoxicillin is administered to a nursing woman.
Pediatric Use
Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed. Dosing of amoxicillin should be modified in pediatric patients 12 weeks or younger (≤3 months). [See DOSAGE AND ADMINISTRATION, Neonates and Infants Aged ≤12 Weeks (≤3 months).]
Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use of amoxicillin and probenecid may result in increased and prolonged blood levels of amoxicillin.
Chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin. This has been demonstrated in vitro; however, the clinical significance of this interaction is not well documented.
As with other penicillins, it may be expected that untoward reactions will be essentially limited to sensitivity phenomena. They are more likely to occur in individuals who have previously demonstrated hypersensitivity to penicillins and in those with a history of allergy, asthma, hay fever, or urticaria.
The following adverse reactions have been reported as associated with the use of penicillins:
Combination Therapy With Clarithromycin and Lansoprazole
In clinical trials using combination therapy with amoxicillin plus clarithromycin and lansoprazole, and amoxicillin plus lansoprazole, no adverse reactions peculiar to these drug combinations were observed. Adverse reactions that have occurred have been limited to those that had been previously reported with amoxicillin, clarithromycin, or lansoprazole.
Triple Therapy
Amoxicillin/Clarithromycin/Lansoprazole
The most frequently reported adverse events for patients who received triple therapy were diarrhea (7%), headache (6%), and taste perversion (5%). No treatment-emergent adverse events were observed at significantly higher rates with triple therapy than with any dual therapy regimen.
Dual Therapy
Amoxicillin/Lansoprazole
The most frequently reported adverse events for patients who received amoxicillin tid plus lansoprazole tid dual therapy were diarrhea (8%) and headache (7%). No treatment-emergent adverse events were observed at significantly higher rates with amoxicillin tid plus lansoprazole tid dual therapy than with lansoprazole alone.
For more information on adverse reactions with clarithromycin or lansoprazole, refer to the ADVERSE REACTIONS section of their respective product information.
In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures as required. If the overdosage is very recent and there is no contraindication, an attempt at emesis or other means of removal of drug from the stomach may be performed. A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms and do not require gastric emptying. 3
Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdosage with amoxicillin. Renal impairment appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of amoxicillin. Amoxicillin may be removed from circulation by hemodialysis.
Amoxicillin capsules, chewable tablets, and oral suspensions may be given without regard to meals. The 400 mg suspension, 400 mg chewable tablet, and the 875 mg tablet have been studied only when administered at the start of a light meal. However, food effect studies have not been performed with the 200 and 500 mg formulations.
Neonates and Infants Aged ≤12 Weeks (≤3 months)
Due to incompletely developed renal function affecting elimination of amoxicillin in this age group, the recommended upper dose of amoxicillin is 30 mg/kg/day divided q12h.
Adults and Pediatric Patients >3 Months
|
||||||||||||||||||||||||||||||||||||||||
| * Dosing for infections caused by less susceptible organisms should follow the recommendations for severe infections. | ||||||||||||||||||||||||||||||||||||||||
| † The children's dosage is intended for individuals whose weight is less than 40 kg. Children weighing 40 kg or more should be dosed according to the adult recommendations. | ||||||||||||||||||||||||||||||||||||||||
| ‡ Each strength of amoxicillin suspension is available as a chewable tablet for use by older children. | ||||||||||||||||||||||||||||||||||||||||
| § NOTE: SINCE PROBENECID IS CONTRAINDICATED IN CHILDREN UNDER 2 YEARS, DO NOT USE THIS REGIMEN IN THESE CASES. | ||||||||||||||||||||||||||||||||||||||||
After reconstitution, the required amount of suspension should be placed directly on the child's tongue for swallowing. Alternate means of administration are to add the required amount of suspension to formula, milk, fruit juice, water, ginger ale, or cold drinks. These preparations should then be taken immediately. To be certain the child is receiving full dosage, such preparations should be consumed in entirety.
All patients with gonorrhea should be evaluated for syphilis (see PRECAUTIONS, Laboratory Tests).
Larger doses may be required for stubborn or severe infections.
General
It should be recognized that in the treatment of chronic urinary tract infections, frequent bacteriological and clinical appraisals are necessary. Smaller doses than those recommended above should not be used. Even higher doses may be needed at times. In stubborn infections, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy. Except for gonorrhea, treatment should be continued for a minimum of 48-72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. It is recommended that there be at least 10 days' treatment for any infection caused by Streptococcus pyogenes to prevent the occurrence of acute rheumatic fever.
H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence
Triple Therapy
Amoxicillin/Clarithromycin/Lansoprazole: The recommended adult oral dose is 1 g amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (q12h) for 14 days (see INDICATIONS AND USAGE).
Dual Therapy
Amoxicillin/Lansoprazole: The recommended adult oral dose is 1 g amoxicillin and 30 mg lansoprazole, each given 3 times daily (q8h) for 14 days. (See INDICATIONS AND USAGE.)
Please refer to the CONTRAINDICATIONS and WARNINGS sections of the clarithromycin and the lansoprazole product information, and for information regarding dosing in elderly and renally impaired patients.
Dosing Recommendations for Adults With Impaired Renal Function
Patients with impaired renal function do not generally require a reduction in dose unless the impairment is severe. Severely impaired patients with a glomerular filtration rate of <30 ml/min should not receive the 875 mg tablet. Patients with a glomerular filtration rate of 10-30 ml/min should receive 500 or 250 mg every 12 hours, depending on the severity of the infection. Patients with a less than 10 ml/min glomerular filtration rate should receive 500 or 250 mg every 24 hours, depending on severity of the infection.
Hemodialysis patients should receive 500 or 250 mg every 24 hours, depending on severity of the infection. They should receive an additional dose both during and at the end of dialysis.
There are currently no dosing recommendations for pediatric patients with impaired renal function.
References
1.Amoxil Capsules
Each capsule contains 250 or 500 mg amoxicillin as the trihydrate. The cap and body of the 250 mg capsule are imprinted with the product name "AMOXIL" and "250"; the cap and body of the 500 mg capsule are imprinted with "AMOXIL" and "500".
Storage: Store at or below 20°C (68°F). Dispense in a tight container.
Amoxil Tablets
Each tablet contains 500 or 875 mg amoxicillin as the trihydrate. Each film-coated, capsule-shaped, pink tablet is debossed with "AMOXIL" centered over "500" or "875," respectively. The 875 mg tablet is scored on the reverse side.
Storage: Store at or below 25°C (77°F). Dispense in a tight container.
Amoxil Chewable Tablets
Each cherry-banana-peppermint-flavored tablet contains 200 or 400 mg amoxicillin as the trihydrate. The 200 and 400 mg pale pink round tablets are imprinted with the product name "AMOXIL" and "200" or "400" along the edge of one side.
Storage: Store at or below 25°C (77°F). Dispense in a tight container.
Amoxil for Oral Suspension
Each 5 milliliter of reconstituted strawberry-flavored suspension contains 125 mg amoxicillin as the trihydrate. Each 5 ml of reconstituted bubble-gum-flavored suspension contains 200, 250, or 400 mg amoxicillin as the trihydrate.
Storage: Store unreconstituted powder at or below 20°C (68°F).
Note: SHAKE WELL BEFORE USING. Keep bottle tightly closed. Any unused portion of the reconstituted suspension must be discarded after 14 days. Refrigeration preferable, but not required.
Amoxil Pediatric Drops for Oral Suspension
Each ml of bubble-gum-flavored reconstituted suspension contains 50 mg amoxicillin as the trihydrate.
Storage: Store at or below 20°C (68°F).
Note: SHAKE WELL BEFORE USING. Keep bottle tightly closed. Any unused portion of the reconstituted suspension must be discarded after 14 days. Refrigeration preferable, but not required.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||